PT792458E - Metodos para auxilio no diagnostico da doenca de alzheimer por medicao do peptido amiloide-beta (x-41) e de tau - Google Patents

Metodos para auxilio no diagnostico da doenca de alzheimer por medicao do peptido amiloide-beta (x-41) e de tau

Info

Publication number
PT792458E
PT792458E PT95939892T PT95939892T PT792458E PT 792458 E PT792458 E PT 792458E PT 95939892 T PT95939892 T PT 95939892T PT 95939892 T PT95939892 T PT 95939892T PT 792458 E PT792458 E PT 792458E
Authority
PT
Portugal
Prior art keywords
alzheimer
diagnosis
disease
amyloid
tau
Prior art date
Application number
PT95939892T
Other languages
English (en)
Inventor
Peter A Seubert
Dale B Schenk
Vigo-Pelfrey Carmen
Barbour Robin
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT792458(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/339,141 external-priority patent/US6114133A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of PT792458E publication Critical patent/PT792458E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT95939892T 1994-11-14 1995-11-13 Metodos para auxilio no diagnostico da doenca de alzheimer por medicao do peptido amiloide-beta (x-41) e de tau PT792458E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/339,141 US6114133A (en) 1994-11-14 1994-11-14 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US41900895A 1995-04-07 1995-04-07

Publications (1)

Publication Number Publication Date
PT792458E true PT792458E (pt) 2005-02-28

Family

ID=26991508

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95939892T PT792458E (pt) 1994-11-14 1995-11-13 Metodos para auxilio no diagnostico da doenca de alzheimer por medicao do peptido amiloide-beta (x-41) e de tau

Country Status (11)

Country Link
US (4) US7427392B1 (pt)
EP (2) EP0792458B1 (pt)
JP (2) JP3634375B2 (pt)
AT (1) ATE278957T1 (pt)
AU (1) AU705907B2 (pt)
CA (1) CA2205359C (pt)
DE (1) DE69533623T2 (pt)
DK (1) DK0792458T3 (pt)
ES (1) ES2230551T3 (pt)
PT (1) PT792458E (pt)
WO (1) WO1996015452A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO2000014546A1 (en) * 1998-09-08 2000-03-16 Innogenetics N.V. Tau as a marker for early cns damage
EP1309341A2 (en) * 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20090123952A1 (en) * 2004-11-12 2009-05-14 Pfizer, Inc. Method of Measuring Amyloid-Beta Peptides
WO2007044094A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
JP2010515717A (ja) 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
EP1944314A1 (en) * 2007-01-11 2008-07-16 Philipps-Universität Marburg Diagnosis of Alzheimer's disease and other neurodementing disorders
WO2008124066A1 (en) 2007-04-05 2008-10-16 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
EP2009445A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
EP2020602A1 (en) * 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
CA2753586A1 (en) * 2009-02-24 2010-09-02 Winton G. Gibbons Detection of complexes of tau and amyloid
SI2408807T1 (sl) * 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
DE102011057021A1 (de) 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
JP5850374B2 (ja) 2012-01-27 2016-02-03 パナソニックヘルスケア株式会社 アルツハイマー病の診断補助方法、及び診断システム
JP6293731B2 (ja) 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
PE20150646A1 (es) 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2495266B8 (es) 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
CA2902026C (en) * 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CN105143258B (zh) 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
KR20140128230A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
KR101890978B1 (ko) 2014-06-17 2018-08-24 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
WO2020098936A1 (fr) 2018-11-14 2020-05-22 Qynapse Procede de determination d'un modele de prediction, procede de prediction de l'evolution d'un k-uplet de marqueurs mk et dispositif associe
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
EA202192891A1 (ru) 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271140A (en) 1978-01-23 1981-06-02 Baxter Travenol Laboratories, Inc. Method and composition for double receptor, specific binding assays
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS6267297A (ja) 1985-09-18 1987-03-26 Hitachi Ltd ポンプの軸受潤滑装置
JPH0779702B2 (ja) 1986-11-17 1995-08-30 サイオス ノバ インコーポレイテッド 組換えアルツハイマーアミロイドタンパク
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
AU7121191A (en) 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
JPH04252956A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパク質の測定方法、試薬及びキット
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
JPH04252955A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd 蛋白質の測定方法、試薬及びキット
EP0620849B1 (en) 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
DE667959T1 (de) 1992-10-26 2000-04-20 Dale B Schenk VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID.
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
JP4252955B2 (ja) 2002-07-01 2009-04-08 ソニー エリクソン モバイル コミュニケーションズ， エービー 電子通信装置に対してテキストを入力する方法
AU2003275708A1 (en) 2002-10-29 2004-05-25 Hoya Corporation Chemically strengthened glass, substrate for information recording medium and information recording medium
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム

Also Published As

Publication number Publication date
JP3634375B2 (ja) 2005-03-30
WO1996015452A1 (en) 1996-05-23
CA2205359C (en) 2006-07-04
EP0792458A1 (en) 1997-09-03
EP1491889A3 (en) 2005-04-06
US7811769B2 (en) 2010-10-12
AU705907B2 (en) 1999-06-03
US20040265920A1 (en) 2004-12-30
JP2004077499A (ja) 2004-03-11
US7700309B2 (en) 2010-04-20
CA2205359A1 (en) 1996-05-23
ES2230551T3 (es) 2005-05-01
US20040253643A1 (en) 2004-12-16
EP1491889A2 (en) 2004-12-29
AU4154496A (en) 1996-06-06
EP0792458B1 (en) 2004-10-06
DK0792458T3 (da) 2005-01-31
US7427392B1 (en) 2008-09-23
ATE278957T1 (de) 2004-10-15
JPH10509797A (ja) 1998-09-22
DE69533623D1 (de) 2004-11-11
US20050069968A1 (en) 2005-03-31
DE69533623T2 (de) 2006-03-02
EP0792458A4 (en) 1999-04-07

Similar Documents

Publication Publication Date Title
PT792458E (pt) Metodos para auxilio no diagnostico da doenca de alzheimer por medicao do peptido amiloide-beta (x-41) e de tau
Kramer et al. Dissociations in hippocampal and frontal contributions to episodic memory performance.
Wassenberg et al. A method to score radiographic change in psoriatic arthritis
DE69434545D1 (de) Flüssigkeitsdosierungs-, -durchfluss- und koagulationssensor für ein medizinisches instrument
NO20074034L (no) Anvendelse av en probe, fremgangsmate og kit for in vitro diagnose samt anvendelse av et monoklonalt eller polyklonalt antistoff
DE68912396D1 (de) Sonde für ein Ultraschall-Operationsinstrument.
WO1998027226A3 (en) Method for determining the prognosis of a patient with a neurological disease
DE69014074D1 (de) Röntgenraster für medizinische röntgenaufnahmen und verfahren zu dessen herstellung und zu dessen verwendung.
WO2003075745A3 (en) Detection, diagnosis, and monitoring of a medical condition or disease with artificial olfactometry
BRPI0214872B8 (pt) unidade peptídica e multipeptídica, método ex vivo para detectar auto-anticorpos de pacientes sofrendo de artrite reumatoide e para seleção de um peptídeo adequado para o diagnóstico da referida doença, e kit de diagnóstico
AUPS293002A0 (en) Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
DK1953556T3 (da) Polypeptidbiomarkører til diagnose af Alzheimer's sygdom
ATE166107T1 (de) Dna, die für ein roggen-pollen-allergen kodiert
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
Dehn et al. Process dissociation procedure: Double dissociations following divided attention and speeded responding
DE60239622D1 (de) Verfahren zur diagnose oder überwachung eines fehlers im zuckerstoffwechsel
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
BR9708421A (pt) Processo para a deteccão de doenca provocada por prions teste diagnostico ou kit de teste e uso do processo
CU23412A3 (es) Diagnóstico y tratamiento de enfermedades utilizando anticuerpos anti-anti-receptor de células t vbeta o péptidos que son reconocidos por dichos anticuerpos, y proteína reguladora de la secreción endocrina 1 (prse1)
KR970706491A (ko) 치주질환 스크리닝 방법(screening method for periodontal disease)
WO2001020533A3 (en) Creation of a database of biochemical data and methods of use
DE69922535D1 (de) Komplex, bestehend aus einem chaperon und beta-amyloidprotein sowie verfahren, die diesen komplex benutzen
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
DE69606651D1 (de) Test zur diagnose von demenz
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases